PPARG and metabolic dysfunction-associated steatohepatitis: Given that PPRAGC1A/PGC-1α interacts with the nuclear receptor PPAR-γ [14], our results also warrant bearing in mind the drug class of thiazolidinediones, which are potent PPAR-γ agonists, that can be used in the treatment of type 2 diabetes to improve hepatic sensitivity to insulin [39,40] and improve fibrosis in nonalcoholic steatohepatitis [40,41].